After raising £5.9 million a fortnight ago, RNA interference specialist Silence Therapeutics says the cash will help pay for the completion of a Phase I trial of its cancer drug Atu027.
Atu027, Silence’s most-advanced internal drug candidate, is a liposomal siRNA formulation targeting PKN3 and is aimed at treating solid cancer. The company plans to begin a Phase Ib/IIa trial by mid-2012 and it hopes to partner the drug during the course of next year.
